---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-013080"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T00:45:03.500876+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeuroBo reports positive Phase 1 SAD data for DA-1726 obesity drug; no serious AEs

## Summary
- 45 obese participants randomized 6:3 DA-1726 vs placebo; drug safe and well tolerated.
- 5 AEs in DA-1726 group vs 3 placebo; no serious adverse events reported.
- Dose-linear PK observed across investigated range; additional cohorts added to find max tolerated dose.
- MAD Part 2 top-line data expected Q1 2025; Part 3 will evaluate early proof of concept.
- CEO cites potential best-in-class profile due to balanced GLP1R and glucagon receptor activation.

## SEC filing metadata
- accession: 0001558370-24-013080
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837024013080/0001558370-24-013080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837024013080/nrbo-20240930x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-013080
- JSON: https://secwatch.observer/filing/0001558370-24-013080.json
- Plain text: https://secwatch.observer/filing/0001558370-24-013080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.